Neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer (BRPC).

被引：1
作者：
Tran, Nguyen H.
Sahai, Vaibhav
Griffith, Kent A.
Nathan, Hari
Kaza, Ravi
Cuneo, Kyle Clifford
Sonnenday, Christopher J.
Cho, Clifford
Lawrence, Theodore Steven
Zalupski, Mark
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Hlth Syst, Ann Arbor, MI USA
[3] Univ Massachusetts, Mem Med Ctr, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.381
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
381
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Hayakawa, S.
    Karasawa, K.
    Fujisawa, T.
    Ito, K.
    Shibata, Y.
    Shimizuguchi, T.
    Nihei, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E236 - E236
  • [42] Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
    Ferrone, Cristina R.
    Marchegiani, Giovanni
    Hong, Theodore S.
    Ryan, David P.
    Deshpande, Vikram
    McDonnell, Erin I.
    Sabbatino, Francesco
    Santos, Daniela Dias
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Faris, Jason E.
    Goyal, Lipika
    Kwak, Eunice L.
    Murphy, Janet E.
    Ting, David T.
    Wo, Jennifer Y.
    Zhu, Andrew X.
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    ANNALS OF SURGERY, 2015, 261 (01) : 12 - 17
  • [43] Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma
    Tinchon, Christoph
    Hubmann, Eva
    Pichler, Angelika
    Keil, Felix
    Pichler, Martin
    Rabl, Hans
    Uggowitzer, Martin
    Jilek, Kurt
    Leitner, Gerhard
    Bauernhofer, Thomas
    ACTA ONCOLOGICA, 2013, 52 (06) : 1231 - 1234
  • [44] Efficacy of Neoadjuvant Chemotherapy Using Gemcitabine and S-1 for Resectable and Borderline Resectable Pancreatic Cancer
    Aoki, T.
    Mori, S.
    Sakuraoka, Y.
    Suzuki, T.
    Nishi, Y.
    Arakawa, T.
    Shimizu, T.
    Tago, K.
    Park, K. H.
    Harada, N.
    Shiraki, T.
    Iso, Y.
    Kubota, K.
    PANCREAS, 2019, 48 (10) : 1404 - 1404
  • [45] Neoadjuvant GTX Chemotherapy and IMRT-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
    Patel, Manish
    Hoffe, Sarah
    Malafa, Mokenge
    Hodul, Pamela
    Klapman, Jason
    Centeno, Barbara
    Kim, Jongphil
    Helm, James
    Valone, Tiffany
    Springett, Gregory
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (02) : 155 - 161
  • [46] The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuvant FOLFIRINOX
    Barenboim, Alex
    Mercer, Diego
    Sahnan, Kapil
    Gaffan, Alex
    Goren, Or
    Halperin, Sharon
    Brazowski, Eli
    Pelles Avraham, Sharon
    Klausner, Joseph M.
    Lubezky, Nir
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [47] Outcomes of patients with borderline-resectable pancreatic cancer treated with FOLFIRINOX versus gemcitabine plus nab-paclitaxel.
    Templeton, Shaina D'Lee
    Moser, Michael
    Chalchal, Haji I.
    Shaw, John
    Luo, Yigang
    Zaidi, Adnan
    Ahmed, Shahid
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [48] Neoadjuvant multimodal treatment of borderline resectable (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) in Mexico.
    Rosas Camargo, Vanessa
    Martos Armedariz, Edgar Omar
    Cisneros Cordero, Miriam Heidi
    Nieto Garcia, Zuleyma
    Flores Balcazar, Christian Haydee
    Meneses Medina, Monica Isabel
    Chan Nunez, Carlos
    Gamboa Dominguez, Armando
    Huitzil Melendez, Fidel David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [49] Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma A Retrospective Cohort Study
    Paniccia, Alessandro
    Edil, Barish H.
    Schulick, Richard D.
    Byers, Joshua T.
    Meguid, Cheryl
    Gajdos, Csaba
    McCarter, Martin D.
    MEDICINE, 2014, 93 (27)
  • [50] Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
    Janssen, Quisette
    van Dam, Jacob L.
    Besselink, Marc G. H.
    Homs, Marjolein Y. V.
    van Tienhoven, Geertjan
    Wilmink, Johanna W.
    Koerkamp, Bas Groot
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345